Steroid solutions more likely to be contaminated

Article

Ophthalmic solutions that contain steroids are 5.8 times more likely to be contaminated than steroid-free solutions.

Ophthalmic solutions that contain steroids are 5.8 times more likely to be contaminated than steroid-free solutions, according to the results of a study published online ahead of print in the British Journal of Ophthalmology.

Danny Kauffmann Jokl, MD and colleagues from Columbia University and New York Medical College, USA conducted a study to assess the frequency of contamination of ophthalmic solutions in a long-term care facility. A total of 123 solutions used for patient treatment were cultured for bacteria.

Ten (8%) of the multiple dose solutions were contaminated with bacteria: four (50%) of eight steroid containing anti-inflammatory solutions, two (33%) of six combination antimicrobial and steroid containing anti-inflammatory solutions, two (6%) of 34 solutions for glaucoma treatment and two (4%) of 57 medications for dry eye. No mydriatic, miotic or non-combination antimicrobial solutions were contaminated.

Proteus mirabilis was found in eight (80%) of the 10 contaminated solutions. Thirty percent of the contaminated bottles, upon visual examination, were considered "dirty".

It was discovered that steroid-containing solutions are 5.8 times more likely to be contaminated than steroid-free solutions. The authors believe that the frequent contamination during reuse of certain steroid containing solutions raises the question of whether single-use solutions may offer a safer alternative.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.